Is 5 Mono

Isosorbide Mononitrate, the active ingredient in Is 5 Mono, is a nitrate vasodilator presented as an oral tablet for oral use. It is indicated for the treatment of angina pectoris and chronic heart failure in adult patients. GNH USA supplies Is 5 Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isosorbide Mononitrate is employed in the management of coronary artery disease and related cardiovascular conditions. - Angina pectoris: reduces the frequency and severity of chest pain episodes. - Chronic heart failure: improves exercise tolerance and alleviates dyspnoea. - Ischemic heart disease: helps control myocardial oxygen demand and prevents anginal attacks.

Common Side Effects: - Headache: mild to moderate, often transient. - Dizziness or light‑headedness, especially on standing. - Flushing of the face or neck. - Hypotension: mild reduction in blood pressure. - Nausea or abdominal discomfort. - Palpitations or tachycardia.

Serious or Rare Side Effects: - Severe hypotension leading to syncope. - Allergic reactions such as rash, pruritus, or angio‑edema. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Myocardial infarction (rare, usually in patients with pre‑existing coronary disease). - Life‑threatening arrhythmias. - Methemoglobinemia (very rare).

Before initiating therapy, consider the following precautions: - Concomitant nitrates: avoid combined use to prevent profound hypotension. - Phosphodiesterase‑5 inhibitors: do not co‑administer due to risk of severe blood pressure fall. - Renal impairment: dose may need adjustment; monitor renal function. - Hepatic disease: use with caution; monitor liver enzymes. - Abrupt discontinuation: taper dose to reduce rebound angina. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Isosorbide Mononitrate may interact with several drug classes. Major Interactions (Avoid): - Other nitrates (e.g., nitroglycerin, isosorbide dinitrate): risk of additive hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil, tadalafil): can cause dangerous blood pressure drops. - Potent antihypertensives (e.g., clonidine, hydralazine): may lead to excessive vasodilation. Moderate Interactions (Monitor Closely): - Diuretics: may enhance hypotensive effect; monitor blood pressure. - ACE inhibitors or ARBs: combined effect on blood pressure requires observation. - Beta‑blockers and calcium‑channel blockers: monitor for additive cardiovascular effects.